Active Ingredient: MACIMORELINE
Macimorelin is associated with a statistically significant, dose-dependent prolongation of the QT interval. In a thorough QT study of 60 healthy subjects, a single supratherapeutic dose (2.0 mg/kg, which is 4x the clinical dose) caused a maximum mean QTcF increase (ΔΔQTcF) of 9.61 ms (90% CI: 7.81–11.41 ms) at 4 hours post-dose. The effect is transient, appearing 3 to 4 hours after the peak plasma concentration (Cmax) and returning to baseline by 5 hours. Due to this risk, macimorelin should be avoided in patients with congenital or acquired long QT syndrome and with concomitant QT-prolonging drugs.
https://doi.org/10.1002/cpdd.872